This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint
by Zacks Equity Research
Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.
NVSPositive Net Change AGIOPositive Net Change AKROPositive Net Change
biotechnology medical
Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
NVSPositive Net Change BMYPositive Net Change LGNDNegative Net Change
biotechnology
Intercept (ICPT) to Restructure Operations, Cut Workforce
by Zacks Equity Research
Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.
LGNDNegative Net Change ICPTPositive Net Change VKTXPositive Net Change
biotechnology pharmaceuticals
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.
NVSPositive Net Change GILDNegative Net Change LGNDNegative Net Change
biotechnology
Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate
by Zacks Equity Research
Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.
NVSPositive Net Change AMLXPositive Net Change AKROPositive Net Change
biotechnology medical
Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata
by Zacks Equity Research
Pfizer's (PFE) Litfulo becomes the first kinase inhibitor approved for treating severe alopecia areata in adolescents, following FDA's approval.
NVSPositive Net Change PFEPositive Net Change AKROPositive Net Change
biotechnology medical
Gilead Sciences (GILD) Announces Positive HDV Treatment Data
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.
NVSPositive Net Change GILDNegative Net Change LGNDNegative Net Change
biotechnology pharmaceuticals
Intercept (ICPT) NDA for NASH Treatment Gets CRL From FDA
by Zacks Equity Research
Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
LGNDNegative Net Change ICPTPositive Net Change MDGLPositive Net Change
biotechnology pharmaceuticals
Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate
by Zacks Equity Research
Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.
AZNNegative Net Change PIRSPositive Net Change AKROPositive Net Change
biotechnology medical
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
by Zacks Equity Research
Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.
ADMAPositive Net Change AGLEPositive Net Change AKROPositive Net Change
biotechnology medical
bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) gene therapy lovotibeglogene autotemcel gets Priority Review in the United States for sickle cell disease.
NVSPositive Net Change LGNDNegative Net Change
biotechnology pharmaceuticals
Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More
by Zacks Equity Research
Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.
GSKPositive Net Change LLYNegative Net Change MRSNNegative Net Change ACLXNo Net Change
biotechnology biotechs
Should You Buy CVRx (CVRX) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CVRXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy American Airlines (AAL) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AALNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate
by Zacks Equity Research
Alderya's (ALDX) shares decline on receiving a complete response letter for an investigational candidate, ADX-2191, treating primary vitreoretinal lymphoma.
ADMAPositive Net Change ALDXNegative Net Change AKROPositive Net Change
biotechnology medical
Denali (DNLI) Provides Update on Hunter Syndrome Study
by Zacks Equity Research
Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).
ADMAPositive Net Change DNLIPositive Net Change AKROPositive Net Change
biotechnology medical
Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal
by Zacks Equity Research
Merck's (MRK) late-stage study evaluating Keytruda in advanced gastric cancer fails to meet one of the primary endpoints.
MRKNegative Net Change ADMAPositive Net Change AKROPositive Net Change
biotechnology medical
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
by Zacks Equity Research
Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.
NVSPositive Net Change GILDNegative Net Change LGNDNegative Net Change ACLXNo Net Change
biotechnology pharmaceuticals
Should You Buy Nutanix (NTNX) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NTNXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Credicorp (BAP)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BAPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly
by Zacks Equity Research
Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease.
LLYNegative Net Change VRTXPositive Net Change AKROPositive Net Change
biotechnology gene-editing medical
Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data
by Zacks Equity Research
Bristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable responses in relapsed or refractory follicular lymphoma and mantle cell lymphoma.
NVSPositive Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs
Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS
by Zacks Equity Research
Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.
ADMAPositive Net Change RETAPositive Net Change AKROPositive Net Change
biotechnology medical
Bristol Myers (BMY) Gets FDA Nod for Data Addition to Camzyos
by Zacks Equity Research
Bristol Myers (BMY) receives FDA approval for additional data to be added to the label of the heart drug Camzyos.
NVSPositive Net Change BMYPositive Net Change LGNDNegative Net Change
biotechnology biotechs
Mersana (MRSN) Down on Partial Ovarian Cancer Study Hold
by Zacks Equity Research
Mersana's (MRSN) shares decline on partial clinical hold by the FDA on UP-NEXT and UPGRADE-A studies evaluating upifitamab rilsodotin to treat platinum-sensitive ovarian cancer.
JNJPositive Net Change ADMAPositive Net Change MRSNNegative Net Change
biotechnology medical